265 related articles for article (PubMed ID: 31954535)
41. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
42. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
[TBL] [Abstract][Full Text] [Related]
43. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
[TBL] [Abstract][Full Text] [Related]
44. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of lymph node involvement in ovarian serous borderline tumors.
Lesieur B; Kane A; Duvillard P; Gouy S; Pautier P; Lhommé C; Morice P; Uzan C
Am J Obstet Gynecol; 2011 May; 204(5):438.e1-7. PubMed ID: 21349494
[TBL] [Abstract][Full Text] [Related]
46. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
[TBL] [Abstract][Full Text] [Related]
47. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
[TBL] [Abstract][Full Text] [Related]
48. Histologic subtypes and laterality of primary epithelial ovarian tumors.
Boger-Megiddo I; Weiss NS
Gynecol Oncol; 2005 Apr; 97(1):80-3. PubMed ID: 15790441
[TBL] [Abstract][Full Text] [Related]
49. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
Voutsadakis IA
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
[TBL] [Abstract][Full Text] [Related]
50. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
Liao CI; Chow S; Chen LM; Kapp DS; Mann A; Chan JK
Gynecol Oncol; 2018 May; 149(2):318-323. PubMed ID: 29514737
[TBL] [Abstract][Full Text] [Related]
51. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Significance of Transitional Cell Carcinoma-Like Morphology of High-Grade Serous Ovarian Carcinoma: A Comparative Study.
Nasioudis D; Sisti G; Kanninen TT; Fambrini M; Di Tommaso M
Int J Gynecol Cancer; 2016 Nov; 26(9):1624-1629. PubMed ID: 27575630
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
54. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiological Aspects and Risk Factors].
Ouldamer L; Body G; Daraï E; Bendifallah S
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):239-247. PubMed ID: 32004787
[TBL] [Abstract][Full Text] [Related]
55. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
Matsuo K; Machida H; Takiuchi T; Grubbs BH; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2017 Mar; 144(3):496-502. PubMed ID: 28131526
[TBL] [Abstract][Full Text] [Related]
56. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
[TBL] [Abstract][Full Text] [Related]
57. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
58. Do survivors of borderline ovarian tumors have susceptibility to secondary primary malignancies? A SEER population-based study.
Wang J; Du Y; Kang Y
Int J Gynaecol Obstet; 2024 Jun; 165(3):1229-1236. PubMed ID: 38205842
[TBL] [Abstract][Full Text] [Related]
59. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244
[TBL] [Abstract][Full Text] [Related]
60. Trends of low-grade serous ovarian carcinoma in the United States.
Matsuo K; Machida H; Grubbs BH; Sood AK; Gershenson DM
J Gynecol Oncol; 2018 Jan; 29(1):e15. PubMed ID: 29185273
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
